Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L.

J Natl Compr Canc Netw. 2017 Dec;15(12):1520-1541. doi: 10.6004/jnccn.2017.0175.

PMID:
29223990
2.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
3.

Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.

Dotan E, Devarajan K, D'Silva AJ, Beck A, Kloth DD, Cohen SJ, Denlinger C.

Clin Colorectal Cancer. 2014 Sep;13(3):192-8. doi: 10.1016/j.clcc.2014.05.003. Epub 2014 Jun 26.

4.

Myeloid growth factors.

Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1266-90.

PMID:
24142827
5.

Antiemesis.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Michaud LB, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba SG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):456-85. No abstract available.

PMID:
22491046
6.

Myeloid growth factors.

Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Aug 1;9(8):914-32. No abstract available.

PMID:
21900221
7.
8.

Antiemesis. Clinical Practice Guidelines in Oncology.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, Todaro B, Urba S.

J Natl Compr Canc Netw. 2009 May;7(5):572-95. No abstract available.

PMID:
19460282
9.

Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy.

Bleicher RJ, Kloth DD, Robinson D, Axelrod P.

J Surg Oncol. 2009 May 1;99(6):356-60. doi: 10.1002/jso.21240.

PMID:
19189298
10.

Myeloid growth factors.

Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Jan;7(1):64-83. No abstract available.

PMID:
19176207
11.

New pharmacologic findings for the treatment of PONV and PDNV.

Kloth DD.

Am J Health Syst Pharm. 2009 Jan 1;66(1 Suppl 1):S11-8. doi: 10.2146/ashp080462.

PMID:
19106333
12.

Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.

Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ.

Pharmacotherapy. 2008 May;28(5 Pt 2):1S-15S. doi: 10.1592/phco.28.5supp.1S.

PMID:
18447704
13.

Myeloid growth factors. Clinical practice guidelines in oncology.

Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Feb;5(2):188-202. No abstract available.

PMID:
17335688
14.

Antiemesis.

Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, McNulty R, Nabati L, Todaro B, Urba S, Yowell S; National comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Jan;5(1):12-33. No abstract available.

PMID:
17239323
15.

Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model.

McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ.

J Support Oncol. 2006 Nov-Dec;4(10):524-9.

PMID:
17136870
16.

Myeloid growth factors clinical practice guidelines in oncology.

Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jul;3(4):540-55. No abstract available.

PMID:
16038645

Supplemental Content

Loading ...
Support Center